Subtitle:

Gene therapy of cardiovascular diseases

Publisher:

Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN

Abstract:

Gene therapy is suggested to be beneficial for the treatment of diseases whichare difficult or impossible to be cured by classical pharmacotherapy. Thus, the transfer of genetic material of potential therapeutic properties may be particularly helpfulin the treatment of hereditary genetic disorders and cancer. However, serious technical obstacles, especially the lack of efficient vectors for the delivery oftherapeutic genes have so far prevented the achievement of convincing therapeutic effects. On theother hand, the complications of atherosclerosis, such as heart or peripheral ischaemia, seem to be good candidates for genetic strategies aimed particularly at stimulation of angiogenesis. As in this case therapeutic genes should be expressed locallyand in a short time there is a good chance that the application ofthis therapy will takeplace earlier than in the case of other disorders. In this paper the first gene therapyclinical trials in human cardiovascular diseases are described. The latest investigationson the basic mechanisms of the blood vessel wall physiology and relationships between factors involved in angiogenesis are also briefly mentioned

Relation:

Biotechnologia, vol.48, 1 (2000)-.

Volume:

48

Issue:

1

Start page:

135

End page:

146

Detailed Resource Type:

Artykuł

Format:

application/pdf

Resource Identifier:

0860-7796 ; oai:rcin.org.pl:142201 ; IChB B-44

Source:

Biblioteka Instytutu Chemii Bioorganicznej PAN

Language:

pol

Language of abstract:

eng

Temporal coverage:

1988-2010

Rights:

Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0

Terms of use:

-

Digitizing institution:

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Original in:

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Projects co-financed by:

Program Operacyjny Polska Cyfrowa, lata 2014-2020, Działanie 2.3 : Cyfrowa dostępność i użyteczność sektora publicznego; środki z Europejskiego Funduszu Rozwoju Regionalnego oraz współfinansowania krajowego z budżetu państwa

Access:

Otwarty